-
Artificial Tears Eye Drops Recall Involving EzriCare and Delsam Pharma’s Products in February 2023
Serious Infections Causing Vision Loss Have Been Linked to the Use of EzriCare Artificial Tears Lubricant Eye Drops (Posted by Tom Lamb at Drug Injury Watch) Today we pick up where our article from last…
-
EzriCare Artificial Tears Associated With Eye Infections: February 2023 CDC Warnings Issued
CDC Recommends Patients Stop Using EzriCare Artificial Tears Products Pending Additional Guidance For These OTC Eye Drops (Posted by Tom Lamb at Drug Injury Watch) On February 1, 2023, the US Centers for Disease Control…
-
Valtrex Associated With Serious Skin Reaction DRESS Side Effect That Can Be Fatal, Says Health Canada
Canadian Product Monograph for Valtrex Now Warns About Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (Posted by Tom Lamb at Drug Injury Watch) Valtrex (valacyclovir) is a long-established treatment for cold sores,…
-
Tepezza Hearing Loss: Cases of This Drug Side Effect Reviewed in Various Medical Journal Articles
This Treatment for Thyroid Eye Disease Was Approved by FDA in 2020, With Hearing Problems Reported Soon Thereafter (Posted by Tom Lamb at Drug Injury Watch) We recently wrote about Tepezza hearing loss cases in…
-
Tepezza Hearing Side Effects Include Deafness, Sound Sensitivity, and Tinnitus, Resulting in Tepezza Drug Injury Lawsuits
Tepezza Linked to Hypoacusis, Hyperacusis, Autophony, Other Hearing Problems Which May be Irreversible and Permanent (Posted by Tom Lamb at Drug Injury Watch) Tepezza is a relatively new treatment for Thyroid Eye Disease, approved by…
-
Copiktra Risk-Benefit Profile Update Following the Recent September 2022 FDA Advisory Committee Meeting
Issue: Whether Copiktra Risk-Benefit Profile is Still Favorable as a Third-Line CLL/SLL Cancer Treatment; Final Vote: "No" (Posted by Tom Lamb at Drug Injury Watch) We concluded our July 5, 2022 article, "Using Copiktra for…